製品番号: HY-109582

ADT-OH

(別名: 5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione; ACS 1)

4 Cited Publications

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.55%
CAS 番号: 18274-81-2
分子式: C₉H₆OS₃
分子量:226.35

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

ADT-OH 構造式

CAS 番号: 18274-81-2

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (4)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

ADT-OH is a hydrogen sulfide-releasing donor. ADT-OH induces apoptosis and upregulates FADD. ADT-OH inhibits FAK/Paxillin. ADT-OH has the potential for the research of cancer diseases^[1]^[5].

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	>40 μM Compound: ADT-OH	Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
A549	IC₅₀	>50 μM Compound: ADT-OH	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
A549	IC₅₀	27.57 μM Compound: ADT-OH	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
A549	IC₅₀	66 μM Compound: ADTOH	Antiproliferative activity against human A549 cells after 3 days Antiproliferative activity against human A549 cells after 3 days	[PMID: 18294844]
A549	IC₅₀	66 μM Compound: ADTOH	Antiproliferative activity against human A549 cells after 48 hrs Antiproliferative activity against human A549 cells after 48 hrs	[PMID: 20576572]
B16	IC₅₀	>50 μM Compound: 6; ADT-OH	Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31877536]
Bel-7402	IC₅₀	>50 μM Compound: ADT-OH	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
Bel-7402	IC₅₀	>50 μM Compound: ADTOH; 5	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 29635169]
Caco-2	IC₅₀	35.47 μM Compound: ADTOH; 5	Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 29635169]
DU-145	IC₅₀	12.71 μM Compound: ADT-OH	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HCT-116	IC₅₀	>50 μM Compound: 6; ADT-OH	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31877536]
HeLa	IC₅₀	0.45 μM Compound: ADTOH	Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay Inhibition of HDAC in human HeLa cells extracts after 60 mins by fluorescence assay	[PMID: 20576572]
HeLa	IC₅₀	0.45 μM Compound: ADTOH	Inhibition of human HDAC in HeLa cells Inhibition of human HDAC in HeLa cells	[PMID: 18294844]
HeLa	IC₅₀	6.48 μM Compound: ADT-OH	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HepG2	IC₅₀	>50 μM Compound: 6; ADT-OH	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31877536]
HepG2	IC₅₀	13.76 μM Compound: ADT-OH	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
HL-60	IC₅₀	25.9 μM Compound: ADTOH; 5	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29635169]
HT-29	IC₅₀	35 μM Compound: ADT-OH	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24273639]
K562	IC₅₀	>50 μM Compound: 6; ADT-OH	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31877536]
K562	IC₅₀	>50 μM Compound: ADT-OH	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
L02	IC₅₀	>50 μM Compound: 6; ADT-OH	Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 31877536]
L02	IC₅₀	>50 μM Compound: ADT-OH	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
L02	IC₅₀	16.79 μM Compound: ADT-OH	Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
MCF7	IC₅₀	>50 μM Compound: 6; ADT-OH	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31877536]
MCF7	IC₅₀	>50 μM Compound: ADTOH; 5	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29635169]
MDA-MB-231	IC₅₀	>50 μM Compound: 2; ADT	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38104376]
MDA-MB-231	IC₅₀	33.19 μM Compound: ADT-OH	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay	[PMID: 37329677]
PBMC	IC₅₀	>100 μM Compound: ADTOH; 5	Antiproliferative activity against human PBMC cells after 72 hrs by MTT assay Antiproliferative activity against human PBMC cells after 72 hrs by MTT assay	[PMID: 29635169]
PBMC	IC₅₀	>50 μM Compound: 6; ADT-OH	Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 31877536]
PBMC	IC₅₀	>50 μM Compound: ADT-OH	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
SGC-7901	IC₅₀	>50 μM Compound: ADT-OH	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
SGC-7901	IC₅₀	>50 μM Compound: ADTOH; 5	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 29635169]

体外実験

ADT-OH (0-200 μM, 24-48 h) significantly inhibits metastasis of TNBC cells (MDA-MB-231 and 4T1-Luci) in the absence of proliferation inhibition^[2].
ADT-OH (7.5-120 μM, 48 h) synergistically enhances the antitumor activity of celecoxib in human colorectal cancer cells HCT116^[3].
ADT-OH promotes self-renewal and antiapoptosis ability of cultured NPCs^[4].
ADT-OH exhibits anti-metastatic activity on malignant melanoma cells through inhibition of FAK/Paxillin signaling pathways^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

ADT-OH (10-30 mg/kg, i.p., every day) reveals a potent anti-metastatic activity in three different mice models, the MDA-MB-231 orthotopic xenograft model, the 4T1-Luci orthotopic model and the 4T1-Luci tail vein metastasis model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MDA-MB-231 orthotopic xenograft model, the 4T1-Luci orthotopic model and the 4T1-Luci tail vein metastasis model^[2]
Dosage:

10, 20, 30 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Had limited effect on the growth of primary tumors, but could significantly suppress the metastasis of MDA-MB-231 tumors.
Had no significant effect on body weight of mice.

化学情報

CAS 番号 18274-81-2
性状 Solid
分子量 226.35
分子式 C₉H₆OS₃
Color Brown to orange
SMILES

S=C1SSC(C2=CC=C(O)C=C2)=C1
別名

5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione; ACS 1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Exp Neurol

Hydrogen sulfide mitigates memory impairments via the restoration of glutamatergic neurons in a mouse model of hemorrhage shock and resuscitation. [Abstract]

2024 Jun:376:114758. PMID: 38513970
SSRN

2024 Apr 18.

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (552.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4179 mL

22.0897 mL

44.1794 mL

5 mM

0.8836 mL

4.4179 mL

8.8359 mL

10 mM

0.4418 mL

2.2090 mL

4.4179 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (9.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (9.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Cai F, et al. ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. Cell Death Dis. 2020;11(1):33. [Content Brief]

[2]. Yu S, et al. ADT-OH exhibits anti-metastatic activity on triple-negative breast cancer by combinatorial targeting of autophagy and mitochondrial fission. Cell Death Dis. 2024 Jun 28;15(6):463. [Content Brief]

[3]. Xu H, et al. ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. Cancer Med. 2023 Aug;12(16):17193-17211. [Content Brief]

[4]. Wei SW, et al. Role of the hydrogen sulfide-releasing donor ADT-OH in the regulation of mammal neural precursor cells. J Cell Physiol. 2022 Jul;237(7):2877-2887. [Content Brief]

[5]. Li CY, et al. Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways. Eur J Pharmacol. 2019 Dec 1;864:172719. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4179 mL	22.0897 mL	44.1794 mL	110.4484 mL
	5 mM	0.8836 mL	4.4179 mL	8.8359 mL	22.0897 mL
	10 mM	0.4418 mL	2.2090 mL	4.4179 mL	11.0448 mL
	15 mM	0.2945 mL	1.4726 mL	2.9453 mL	7.3632 mL
	20 mM	0.2209 mL	1.1045 mL	2.2090 mL	5.5224 mL
	25 mM	0.1767 mL	0.8836 mL	1.7672 mL	4.4179 mL
	30 mM	0.1473 mL	0.7363 mL	1.4726 mL	3.6816 mL
	40 mM	0.1104 mL	0.5522 mL	1.1045 mL	2.7612 mL
	50 mM	0.0884 mL	0.4418 mL	0.8836 mL	2.2090 mL
	60 mM	0.0736 mL	0.3682 mL	0.7363 mL	1.8408 mL
	80 mM	0.0552 mL	0.2761 mL	0.5522 mL	1.3806 mL
	100 mM	0.0442 mL	0.2209 mL	0.4418 mL	1.1045 mL

Keywords

ADT-OH

4 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ADT-OH

Apoptosis Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Human Metabolite Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 ADT-OH

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ADT-OH

Apoptosis Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Human Metabolite Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

MedChemExpress（MCE）の使用を引用している文献 ADT-OH

生物活性

化学情報

Publications (4)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ADT-OH 関連分類

製品番号: HY-109582